Selpercatinib (LOXO-292)
Selpercatinib, a RET-inhibitor for children with solid tumours and brain tumours
Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Recruiting
Summary
In this clinical trial children, adolescents and young adults between 12 and 21 years will be treated with Selpercatinib (Loxo-292).
Selpercatinib specifically inhibits the Receptor-Tyrosine Kinase (RET), meaning it blocks a type of enzyme (kinase) and helps to prevent the cancer cells from growing. Before the treatment starts, the identification of a RET gene alteration must be determined using laboratory testing. Therefore, only advanced tumours with RET-alterations after standard therapy are eligible.
Selpercatinib is taken orally over a 28-day cycle as gelatine capsules or as a liquid suspension.
Main inclusion criteria
- Age: 12 to 21 years
- advanced solid tumors or primary tumors of the central nervous system
- Confirmed alteration of the RET-gene (mutations and fusions)
- Karnofsky or Lansky > 50
Sponsor
Loxo Oncology Inc., wholly owned subsidiary of Eli Lilly and Company